American biotech company Moderna announced it expects to enter Phase 3 of the Clincal Development stage of its mRNA COVID-19 vaccine candidate by July 2020.  Based on feedback from the U.S. Food and Drug Administration (FDA), Moderna plans to conduct a Phase 3 study of 30,000 subjects at 100 microgram (μg) dose level.